
Opinion|Videos|July 31, 2023
Closing Thoughts on Enfortumab Vedotin Plus Pembrolizumab in Patients With Advanced Urothelial Carcinoma
Rohit Gosain, MD, and Rahul Gosain, MD, provide a summary of the key data discussed during their conversation with Jonathan E. Rosenberg, MD, on the phase 2 EV-103 trial in metastatic or locally advanced urothelial carcinoma.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Divarasib Improves Survival Vs Approved KRAS G12C Inhibitors in NSCLC
2
Examining the Strongest Options for Heavily Pretreated Myeloma After Bispecific Therapy
3
Zoldonrasib Combos, Including With Daraxonrasib, Yield High Response Rates in PDAC
4
FDA OKs ProstACT Trial Part 2 Protocol for Metastatic Prostate Cancer
5











































